Skip to main content
Signal8

REGENERON PHARMACEUTICALS, INC. (REGN) Form 10-Q — Oct 30, 2026

$REGNForm 10-QFiled Oct 30, 2026, 6:55 AM ET0000872589-26-000034Original filing

Regeneron's Q3 2026 revenue rose 36% year-over-year to $5.12 billion with diluted EPS of $18.45 versus $13.62 a year ago, driven by Dupixent global sales of $6.54 billion (+35%) and its share of Sanofi collaboration profits. The quarter also reflects a mixed eye-care picture: EYLEA HD U.S. sales grew 63% globally to $2.85 billion while legacy EYLEA U.S. sales fell 41% on biosimilar competition, leaving combined EYLEA franchise sales down 15%.

Key figures

Eps
18.45
Total Debt
1987000000
Revenue Yoy
36% (Q3 2026 vs Q3 2025: $5,115.8M vs $3,754.3M)
Eps Prior Year
13.62
Shares Outstanding
101,630,713 Common Stock + 1,817,146 Class A as of October 22, 2026
Eylea us q3 sales
399700000
Nine month revenue
$13,011.9M vs $10,458.6M prior year
Eylea hd us q3 sales
698800000
Nine month net income
$3,972.8M vs $3,660.3M
Eylea us sales decline
-41% YoY
Nine month diluted eps
37.37
Libtayo global q3 sales
550000000
Sanofi amendment upfront
$1.0 billion (recorded in Q4 2026)
Sanofi amendment milestones
up to $7.0 billion
Quarterly dividend per share
0.94
Revolving credit availability
$750.0 million
Sanofi collaboration revenue q3
2724000000
Repurchase authorization remaining
$2.157 billion
Capital expenditure guidance fy2026
$1.050 billion to $1.100 billion

AI analysis

Red flags5 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.